Results 41 to 50 of about 17,271 (194)
IntroductionAbiraterone acetate is a key therapeutic agent for castration-resistant prostate cancer (CRPC), but the cancer resistance limits its long-term efficacy.
Lizhi Chen +5 more
doaj +1 more source
Objective: This double-blind, placebo-controlled phase 3 study was designed to compare efficacy and safety of abiraterone acetate + prednisone (abiraterone) to prednisone alone in chemotherapy-naïve, asymptomatic or mildly symptomatic metastatic ...
Dingwei Ye +16 more
doaj +1 more source
The schematic diagram depicts a compartmentalized anti‐ferroptotic defense mechanism mediated by GSTA4. GSTA4 is upregulated and localizes to the cytoplasm in ENZR cells, where it detoxifies 4‐HNE via a non‐canonical GSH‐dependent pathway. Under oxidative stress, GSTA4 translocates to mitochondria, interacts with PGAM5, and blocks Drp1 Ser637 ...
Yong Luo +17 more
wiley +1 more source
Steroid sidestep: evading androgen ablation by abiraterone
Tumor mechanisms of abiraterone resistance in clinical prostate cancer are not well defined. Chen and colleagues report that a T878A androgen receptor mutation occurs in a subset of patients progressing while receiving abiraterone, suggesting that this ...
Sharifi, Nima
core +1 more source
Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer [PDF]
Abiraterone suppresses intracrine androgen synthesis via inhibition of CYP17A1. However, clinical evidence suggests that androgen synthesis is not fully inhibited by abiraterone and the sustained androgen production may lead to disease relapse.
Lombard, Alan +5 more
core +1 more source
AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer
Oncogenic activation of PI3K/AKT signaling pathway, together with epigenetic aberrations are the characters of castration-resistant prostate cancer (CRPC).
Yongming Fu +8 more
doaj +1 more source
Drug Repurposing for Treating NCOR‐Related Intellectual Disability
An autism‐associated NCOR1 heterozygous mutation upregulates NRGs and activates NRG backward signaling in hypothalamic GABAergic neurons in mouse models, leading to Gabra2 downregulation and cognitive deficits, which can be therapeutically targeted by repurposing FDA‐approved drugs.
Yan Kong +15 more
wiley +1 more source
Although second-generation therapies like abiraterone (ABI) and enzalutamide (ENZ) benefit patients with castration-resistant prostate cancer (CRPC), drug resistance frequently occurs, eventually resulting in therapy failure.
Ying Zhang +11 more
doaj +1 more source
By integrating knowledge‐augmented artificial intelligence with an oxygen‐supplemented 3D screening platform, a synergistic interaction between berberine and enzalutamide is identified. The framework integrates compound mechanisms of action with disease‐relevant signaling context to prioritize candidate combinations and generate testable pathway‐based ...
Chih‐Hui Lo +15 more
wiley +1 more source
First tumor microenvironment (TME)‐responsive spermine‐loaded hydrogel with autonomous sensing for advanced local therapy of prostate cancer (PCa) is developed. Spermine can be released from the hydrogel to kill the prostate cancer cells specifically under acidic TME.
Ho‐Fai Chau +12 more
wiley +1 more source

